BIOMARIN PHARMACEUTICAL INC reports

Company location: Novato, CA
Fiscal year end: 31 December

BIOMARIN PHARMACEUTICAL INC has filed 2,724 SEC EDGAR filings since 04 May 1999

Filter by type:
10-K
10-Q
8-K
SC13D
SC13G

SEC filing history

Showing 326-350 of 1,000 matching filings.

Per page

25

Current page

14

4

FORM 4 SUBMISSION

Filing date: 02 Mar 2023
Reporting date: 28 Feb 2023
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4 SUBMISSION

Filing date: 02 Mar 2023
Reporting date: 28 Feb 2023
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4 SUBMISSION

Filing date: 02 Mar 2023
Reporting date: 28 Feb 2023
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 28 Feb 2023
Reporting date: 24 Feb 2023
SEC evidence: Open document Open filing
Next action: Verify source filing

10-K File 000-26727

10-K

Filing date: 27 Feb 2023
Reporting date: 31 Dec 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

8-K File 000-26727

8-K

Filing date: 27 Feb 2023
Reporting date: 27 Feb 2023
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

4

FORM 4

Filing date: 14 Feb 2023
Reporting date: 07 Feb 2023
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-56595

SC 13G/A

Filing date: 14 Feb 2023
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

5

FORM 5

Filing date: 13 Feb 2023
Reporting date: 31 Dec 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-56595

SEC SCHEDULE 13G

Filing date: 13 Feb 2023
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

5

FORM 5

Filing date: 10 Feb 2023
Reporting date: 31 Dec 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

5

FORM 5

Filing date: 10 Feb 2023
Reporting date: 31 Dec 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-56595

PRIMECAP MANAGEMENT CO/CA/

Filing date: 09 Feb 2023
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-56595

SCHEDULE 13G/A

Filing date: 09 Feb 2023
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-56595

SC 13G/A filing

Filing date: 03 Feb 2023
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 27 Jan 2023
Reporting date: 25 Jan 2023
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 18 Jan 2023
Reporting date: 13 Jan 2023
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 17 Jan 2023
Reporting date: 13 Jan 2023
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 000-26727

8-K

Filing date: 11 Jan 2023
Reporting date: 09 Jan 2023
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

8-K File 000-26727

8-K

Filing date: 21 Dec 2022
Reporting date: 15 Dec 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

4

FORM 4

Filing date: 15 Dec 2022
Reporting date: 13 Dec 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 15 Dec 2022
Reporting date: 13 Dec 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 06 Dec 2022
Reporting date: 02 Dec 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 06 Dec 2022
Reporting date: 02 Nov 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 28 Nov 2022
Reporting date: 23 Nov 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .